前列地尔联合肾康注射液用于慢性肾衰竭治疗的疗效观察

摘要

Objective To investigate the clinical efficacy and value of alprostadil combined with Shenkang injection in treatment for chronic renal failure (CRF).Methods 92 patients with CRF were randomly divided into observation group and control group,with 46 cases in each group,the control group was given antiinfection,control blood pressure,diet and other conventional treatment,on the basis of conventional therapy observation group was treated with alprostadil Shenkang injection fluid treatment program,patients were observed with clinical efficacy.Results After treatment,all biochemical indicators in the observation group were better than those of the control group (P＜0.05); the total effective rate was 89.13％,significantly higher than that of the control group (54.35％) (P＜0.05).Conclusion The combination therapy of alprostadil and Shenkang injection for CRF can effectively improve the clinical symptoms and delay kidney failure process,and has no adverse reaction,which can be used as a preferred option for the conservative treatment of CRF.%目的 探讨前列地尔联合肾康注射液治疗慢性肾衰竭的临床疗效及应用价值.方法 将92例慢性肾衰竭患者随机分为观察组和对照组各46例,对照组给予抗感染、控制血压、饮食等常规治疗,观察组对常规治疗基础上给予前列地尔与肾康注射液联合治疗方案,观察两组患者临床疗效.结果 观察组治疗后各生化指标均优于对照组(P＜0.05);观察组总有效率为89.13％,明显高于对照组的54.35％(P＜0.05).结论 前列地尔与肾康注射液联合治疗CRF能有效改善患者临床症状、延缓肾衰竭进程,且无不良反应,可作为目前保守治疗CRF的一种较佳方案.